enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON & MONTREAL, April 01, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, ...
PMLive57 分钟
AstraZeneca’s Imfinzi regimen approved by FDA to treat muscle-invasive bladder cancer
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...